声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 2026年2月27日，ST未名（维权）（sz002581）触及涨停，涨停价8.4元，涨幅5%，总市值55.42亿元， 流通市值33.67亿元，截止发稿，总成交额7938.02万元。 根据喜娜AI异动分析，ST未名涨停原因可能如下，药品许可+股权收回+亏损收窄： 1、公司子公司获 得药品经营许可证，这有助于完善医药产业链布局，从长期来看对业务发展有积极影响。同时，公司法 律诉讼胜诉收回厦门未名34%股权并获赔偿，强化了对相关业务的控制权，这两个因素为公司的经营带 来了实质性的利好。 2、公司2025年亏损幅度同比收窄34.46%-59.95%，经营状况有一定改善。在当前 医药行业竞争 ...

山东未名生物医药股份有限公司 关于持股 5%以上股东股份减持完成的公告 公司持股5%以上股东高宝林先生及其一致行动人王明贤先生保证向本公司提 供的信息真实、准确和完整，没有虚假记载，误导性陈述或者重大遗漏；本公司及 董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 11 月 29 日在巨潮资讯网披露了《关于持股 5%以上股东减持股份的预披露公告》（公告 编号：2025-084），持有公司 5%以上股份的股东高宝林先生及其一致行动人王 明贤先生，因自身资金需求，计划自该公告披露之日起 15 个交易日后的 3 个月 内以集中竞价方式、大宗交易方式或两种方式相结合减持公司股份，减持数量合 计不超过 19,792,067 股的公司股份（占公司总股本比例 3%）。 2026 年 1 月 14 日，公司在巨潮资讯网披露《关于持股 5%以上股东权益变动 比例触及 1%整数倍的公告》（公告编号：2026-001）。该次减持完成后，高宝 林先生及其一致行动人王明贤先生合计持有公司股份由 74,622,800 股下降至 70,622,800 股，占公司总 ...

证券代码：002581 证券简称：ST未名 公告编号：2026-005 山东未名生物医药股份有限公司 关于持股 5%以上股东权益变动比例触及 1%整数倍的公告 公司持股5%以上股东高宝林先生保证向本公司提供的信息真实、准确和完整， 没有虚假记载，误导性陈述或者重大遗漏；本公司及董事会全体成员保证公告内容 与信息披露义务人提供的信息一致。 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 11 月 29 日在巨潮资讯网披露了《关于持股 5%以上股东未来减持计划预披露的公告》（公 告编号：2025-084），持有公司 5%以上股份的股东高宝林先生及其一致行动人 王明贤先生，因自身资金需求，计划自该公告披露之日起 15 个交易日后的 3 个 月内以集中竞价方式、大宗交易方式或两种方式相结合减持公司股份，减持数量 合计不超过 19,792,067 股的公司股份（占公司总股本比例 3%）。 2026 年 1 月 14 日，公司在巨潮资讯网披露《关于持股 5%以上股东权益变动 比例触及 1%整数倍的公告》（公告编号：2026-001）。该次减持完成后，高宝 林先生及其一致行动人王明贤先生合计持有公司股份由 ...

Group 1 - The core transaction of ST Weiming on February 3 involved 1.5454 million shares traded, with a total transaction value of 10.5551 million yuan, accounting for 21.38% of the total trading volume for that day [1] - The transaction price was 6.83 yuan per share, representing a discount of 9.54% compared to the market closing price of 7.55 yuan [1] Group 2 - Multiple transactions of ST Weiming on the same day included various trading volumes, with the highest being 39,000 shares at the same price of 6.83 yuan, executed by different brokerage firms [2] - The total transaction amounts for these trades varied, with the highest being 266.37 thousand yuan for each of the 39,000 shares traded [2]

Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 2026年2月3日，ST未名（维权）（sz002581）触及涨停，涨停价7.55元，涨幅5.01%，总市值49.81亿 元，流通市值30.26亿元，截止发稿，总成交额2921.48万元。 根据喜娜AI异动分析，ST未名涨停原因可能如下，创新药研发+经营改善+产业链完善： 1、公司创新 药 SMR001滴眼液获 III 期临床批件，该药物针对 180 亿规模的干眼症市场，具有修复角膜神经的独特 技术优势。创新药研发的进展是刺激股价涨停的重要因素，显示公司在医药领域的技术实力和发展潜 力。 2、公司经营状况有所改善，2026 年 1 月 30 日公布 2025 年报显示亏损小幅减少，归 ...

Summary of Key Points Core Viewpoint - On January 30, ST Weiming executed a block trade of 1.5 million shares, amounting to 10.62 million yuan, which represented 25.05% of the total trading volume for the day, with a transaction price of 7.08 yuan, reflecting a discount of 3.8% compared to the market closing price of 7.36 yuan [1]. Group 1: Trade Details - The block trade involved a total of 1.5 million shares at a price of 7.08 yuan per share [1]. - The total transaction value for the block trade was 10.62 million yuan [1]. - The trade accounted for 25.05% of the total trading volume on that day [1]. Group 2: Trading Parties - The buyers included multiple brokerage firms such as Industrial Securities, Guotou Securities, and Jianghai Securities [2]. - The sellers were primarily from Huatai Securities, with various branches involved in the transaction [2]. - Each buyer purchased 50,000 shares, resulting in a total of 354,000 yuan for each transaction [2].

Core Viewpoint - ST Unimed (002581.SZ) forecasts a significant loss for the fiscal year 2025, with projected revenue between 355 million to 398 million yuan and a net loss attributable to shareholders ranging from 55 million to 90 million yuan, compared to a loss of 137 million yuan in the same period last year [1] Financial Performance - The company expects to report a revenue of 355 million to 398 million yuan for the fiscal year 2025 [1] - The net loss attributable to shareholders is projected to be between 55 million to 90 million yuan, an improvement from the previous year's loss of 137 million yuan [1] - The net profit after deducting non-recurring gains and losses is anticipated to be a loss of 70 million to 105 million yuan, compared to a loss of 111 million yuan in the previous year [1] Operational Challenges - The primary reason for the company's losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has adversely affected related business revenue [1] - The company is actively working on rectification to promote the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]

格隆汇1月29日丨ST未名(002581.SZ)发布2025年度业绩预告，报告期内，实现营业收入3.55亿元-3.98亿 元；归属于上市公司股东的净利润为亏损5,500万元-9,000万元，上年同期亏损1.37亿元；扣除非经常性 损益后的净利润为亏损7,000万元-1.05亿元，上年同期亏损1.11亿元。 本报告期内公司业绩亏损主要原因为控股子公司天津未名生物医药有限公司暂停生产和销售，相关业务 收入受到影响。同时，为推进复产进程，公司积极整改，成本与费用支出持续，导致亏损。 ...

Core Viewpoint - ST Unimed has announced an annual performance forecast indicating a projected net loss attributable to shareholders of the listed company for 2025, estimated between 55 million to 90 million yuan [1] Financial Performance - The expected net profit, excluding non-recurring gains and losses, is projected to be a loss of 70 million to 105 million yuan for the year 2025 [1] - The primary reason for the losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has significantly impacted related business revenue [1] Operational Challenges - The company is actively working on rectification measures to expedite the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]